252 results on '"da Cunha-Bang, Caspar"'
Search Results
2. It is feasible and safe to stop specialized follow-up of asymptomatic lower-risk chronic lymphocytic leukemia
3. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies
4. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
5. Author Correction: Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients
6. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations
7. The diversity of the microbiome impacts chronic lymphocytic leukemia development in mice and humans
8. Supplementary Figure S6 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
9. Data from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
10. Supplementary Table S2 from Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
11. Patients with CLL have a lower risk of death from COVID-19 in the Omicron era
12. Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients
13. Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
14. The Danish Lymphoid Cancer Research (DALY-CARE) data resource: the basis for developing data-driven hematology
15. Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death
16. Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials
17. Trends in underlying causes of death in allogeneic hematopoietic cell transplant recipients over the last decade.
18. “Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation”
19. P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.
20. S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL
21. P629: THE CLL TREATMENT INFECTION MODEL – CLINICAL PROSPECTIVE VALIDATION AS PART OF THE PREVENT-ACALL TRIAL
22. S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL
23. P599: ACALABRUTINIB IMPROVES INNATE IMMUNE FUNCTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
24. Targeting Bruton’s Tyrosine Kinase Across B-Cell Malignancies
25. Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia
26. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
27. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients
28. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
29. Impact of type 2 diabetes on mortality, cause of death, and treatment in chronic lymphocytic leukemia
30. Implementation of the CLL Treatment Infection Model Adjoined to an Electronic Health Record System - Guidelines for Practical Implementation of Data-Driven Models
31. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
32. Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial
33. CLL-IPI applied in Binet A CLL: a nationwide cohort study
34. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
35. The gut microbiome in patients with chronic lymphocytic leukemia
36. Identifying patients with chronic lymphocytic leukemia without need of treatment : End of endless watch and wait?
37. Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial
38. CLL-IPI applied in Binet A CLL:a nationwide cohort study
39. The gut microbiome in patients with chronic lymphocytic leukemia
40. Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia
41. Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?
42. Healthcare Utilization and Comorbidity in Chronic Lymphocytic Leukemia
43. A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial
44. High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial
45. Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial
46. Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia
47. First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial
48. Mapping comorbidity in chronic lymphocytic leukemia:impact of individual comorbidities on treatment, mortality, and causes of death
49. Healthcare Utilization and Comorbidity in Chronic Lymphocytic Leukemia
50. Risk of new malignancies among patients with CLL treated with chemotherapy:results of a Danish population-based study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.